JAGSNPHARM vs SHILPAMED: Stock Comparison
SHILPA MEDICARE is the larger company by market capitalisation. JAGSONPAL PHARMACEUTICALS shows a lower P/E, a higher ROE and a higher dividend yield, while SHILPA MEDICARE shows faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
JAGSNPHARM leads 6; SHILPAMED leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | JAGSNPHARM | SHILPAMED |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | JAGSNPHARM | SHILPAMED |
|---|---|---|
| Live Price | ₹222 | ₹931.7 |
| Day Change | 0.03% | -0.42% |
| Volume | 4,710 | 2.91 L |
| 52-Week High | ₹264.5 | ₹1,095 |
| 52-Week Low | ₹155 | ₹259.5 |
| Distance from 52W High | -16.07% | -14.91% |
Valuation
| Metric | JAGSNPHARM | SHILPAMED |
|---|---|---|
| Market Cap | ₹1,483 Cr | ₹18,776 Cr |
| P/E Ratio | 32.35x | 61.4x |
| P/B Ratio | 6.09x | 7.04x |
| EPS | ₹2 | ₹5.16 |
| Book Value | ₹41.95 | ₹132.49 |
| Dividend Yield | 1.8% | 0.06% |
Growth
| Metric | JAGSNPHARM | SHILPAMED |
|---|---|---|
| Revenue Growth (TTM YoY) | 9.6% | 31.5% |
| EPS Growth (TTM YoY) | 23.8% | 644.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | JAGSNPHARM | SHILPAMED |
|---|---|---|
| ROE | 15.6% | 5.1% |
| ROCE | 16.48% | 5.31% |
| Net Margin | 15% | 15.82% |
| Operating Margin | 20.38% | 27.86% |
| Debt to Equity | 0x | 0.05x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | JAGSNPHARM | SHILPAMED |
|---|---|---|
| Promoter Holding | 25.46%▼ 0.09 pp | 40.13% |
| FII Holding | 2.14%▼ 0.16 pp | 12.11%▲ 0.73 pp |
| DII Holding | 1.65%▲ 1.03 pp | 8.26%▲ 0.21 pp |
| Public Holding | 27.4%▼ 0.63 pp | 39.49%▼ 0.94 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: JAGSONPAL PHARMACEUTICALS and SHILPA MEDICARE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.